Advancing Patient Outcomes
Our mission is to transform the standard of care for more than 800,000 patients in the U.S. living with decompensated cirrhosis. By developing a first-in-class subcutaneous V1aR partial agonist, we aim to safely reverse circulatory dysfunction and prevent life-threatening complications.
First-in-Class Science
Molecular Mechanism
Our first-in-class V1aR partial agonist target receptors in the vascular system, precisely modulating muscle tone to reverse pathological vasodilation without triggering dangerous systemic shifts.
Subcutaneous Delivery
The subcutaneous administration route enables consistent plasma concentrations and improved patient compliance, offering a significant advancement over standard intravenous inpatient therapies.
Clinical Results
Targeted action results in the prevention of complications associated with decompensated cirrhosis, aimed at significantly improving the quality of life for circulatory dysfunction patients.
Discovery
Lead Candidate: RT-101
Current Stage: Preclinical
Establishing clinical-ready formulation and subcutaneous profile for upcoming IND enabling studies.
Preclinical
Phase 1 Initiation
Target: Q2 2027
Phase 2
Phase 3
Connect with Rallidae
We welcome inquiries from potential partners, investors, and stakeholders dedicated to advancing cirrhosis care.
Rallidae Therapeutics, Inc.
California, USA
info@rallidae.com
